Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Journal of Medicinal Chemistry|August 1, 2025
Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine ReceptorAmy E Moritz, Feijun Wang, Nora S Madaras, et al.
Scientific Reports|January 21, 2018
The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ionsChristopher J Draper-Joyce, Ravi Kumar Verma, Mayako Michino, et al.
Angewandte Chemie (International Ed. in English)|February 10, 2024
Discovery of the First-in-Class Inhibitors of Hypoxia Up-Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast ActivationDimitra Papadopoulou, Vasiliki Mavrikaki, Filippos Charalampous, et al.
Molecular Pharmacology|August 6, 2021
Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine ReceptorR Benjamin Free, Caroline A Cuoco, Bing Xie, et al.
Iscience|August 19, 2022
Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptineDespoina Aslanoglou, Suzanne Bertera, Laura Friggeri, et al.
Breast Cancer Research : BCR|November 27, 2015
β2-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasionSarah J Creed, Caroline P Le, Mona Hassan, et al.
Nature|October 15, 2013
Structural basis for modulation of a G-protein-coupled receptor by allosteric drugsRon O Dror, Hillary F Green, Celine Valant, et al.
European Journal of Medicinal Chemistry|June 26, 2026
Dual-target mu opioid-dopamine D3 receptor (MOR-D3R) ligands based on etonitazene: New leads for transforming "nitazenes" into novel analgesicsKhorshada Jahan, Grant Glatfelter, Julie Sanchez, et al.
Molecular Pharmacology|August 3, 2018
Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding SitesKathryn D Luderman, Jennie L Conroy, R Benjamin Free, et al.
Science Signaling|April 3, 2020
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonistsAlexander Gillis, Arisbel B Gondin, Andrea Kliewer, et al.
Pageof 10